About

Aims and scope

Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.

Topics of interest include but are not limited to the following areas of neurodegenerative diseases:

  • Epidemiology and pathogenesis
  • Research into diagnosis and prevention
  • Research into the diease pathogenesis
  • Development of new drugs and cell therapy
  • Drug delivery
  • Rehabilitation

Translational Neurodegeneration offers the opportunity for basis scientists, clinicians and physician-scientists to publish their research and clinical trials in a journal which is applicable to their specific field.

Open access

All articles published by Translational Neurodegeneration are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

As authors of articles published in Translational Neurodegeneration you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

The publication costs for Translational Neurodegeneration are covered by Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China, so authors do not need to pay an article-processing charge for each article accepted for publication.

Indexing services

All articles published in Translational Neurodegeneration are included in:

  • CAS
  • DOAJ
  • Emerging Sources Citation Index
  • PubMed
  • PubMed Central
  • ​Scopus

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.

We are working closely with relevant indexing services including Web of Science (Clarivate Analytics) to ensure that articles published in Translational Neurodegeneration will be available in their databases when appropriate.

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.

Translational Neurodegeneration operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Edited by Shengdi Chen, Translational Neurodegeneration is supported by an expert Editorial Board. Manuscripts are reviewed by internationally recognized experts in the field, selected in part from the journal's Editorial Board. The suitability of manuscripts for publication is assessed solely on criteria of scientific excellence: final decisions are made by the Editor-in-Chief and may include accept, reject, accept following minor revision and resubmit after major revision and further review.

Editorial policies

The editorial policies of Translational Neurodegeneration are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China. Unless otherwise stipulated in these guidelines, all manuscripts submitted to Translational Neurodegeneration should adhere to BioMed Central's editorial policies.

Citing articles in Translational Neurodegeneration

Articles in Translational Neurodegeneration should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Transl Neurodegener [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Transl Neurodegener 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Appeals and complaints

If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.

Why publish your article in Translational Neurodegeneration

High visibility

Translational Neurodegeneration's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Translational Neurodegeneration offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Translational Neurodegeneration gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Translational Neurodegeneration are included in article alerts and regular email updates. Some may be highlighted on Translational Neurodegeneration’s pages and on the BioMed Central homepage.

In addition, articles published in Translational Neurodegeneration may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Translational Neurodegeneration. A list of articles recently press-released by journals published by BioMed Central is available here.

Copyright

As an author of an article published in Translational Neurodegeneration you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.